Respiratory syncytial virus vaccine, adjuvanted (GlaxoSmithKline)

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameRespiratory syncytial virus vaccine, adjuvanted (GlaxoSmithKline)
Drug Alias Name重组呼吸道合胞病毒（RSV）疫苗（AS01E 佐剂系统）RSV Vaccine (GlaxoSmithKline)mRNA-based respiratory syncytial virus vaccine (GlaxoSmithKline)重组呼吸道合胞病毒疫苗（CHO细胞，AS01E佐剂系统）Arexvy +[6] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsRespiratory Syncytial Virus Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcMedical University Of ViennaGlaxosmithkline Biologicals SA +[6] 
Inactive CompaniesClover Biopharmaceuticals USA LLCJohns Hopkins University
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A